Drug Trial Radar · NCT07000123
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
3,103
Actual
Start
May 28, 2025
Primary completion
Jan 11, 2027
Study completion Jan 11, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.
Conditions
- Cardiovascular Disease
Interventions
AZD0780Drug
Participants will receive daily oral dose of AZD0780
PlaceboDrug
Participants will receive daily oral dose of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in LDL-C from baseline to 12 weeksTime frame: Baseline - 12 weeks
Locations
404 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Huntsville, Alabama
Research Site
Irondale, Alabama
Research Site
Mobile, Alabama
Research Site
Gilbert, Arizona
Research Site
Phoenix, Arizona
Research Site
Sun City West, Arizona
Research Site
Garden Grove, California
Research Site
Gardena, California
Research Site
Lancaster, California
Research Site
Lincoln, California
Research Site
San Diego, California
Research Site
San Diego, California
Research Site
Torrance, California
Research Site
West Hills, California
Research Site
Hamden, Connecticut
Research Site
Boca Raton, Florida
Research Site
Hallandale, Florida
Research Site
Hialeah, Florida
Research Site
Inverness, Florida
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
New Port Richey, Florida
Research Site
Orlando, Florida
Research Site
Pembroke Pines, Florida
Research Site
Seminole, Florida
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Decatur, Georgia
Research Site
Peachtree Corners, Georgia
Research Site
Chicago, Illinois
Research Site
Winfield, Illinois
Research Site
Evansville, Indiana
Research Site
Evansville, Indiana
Research Site
Indianapolis, Indiana
Research Site
Ames, Iowa
Research Site
El Dorado, Kansas
Research Site
Wichita, Kansas
Research Site
Owensboro, Kentucky
Research Site
Hammond, Louisiana
Showing 40 of 404 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.